|
Parameters
|
Discovery cohort (N = 194)
|
Validation cohort (N = 172)
|
Independent cohort (N = 73)
|
|---|
|
Age (X ± SD)
|
59.2 ± 10.1
|
59.8 ± 10.2
|
57.6 ± 9.1
|
|
Gender
|
|
Male
|
144 (74.2%)
|
136 (79.1%)
|
52 (71.2%)
|
|
Female
|
50 (25.8%)
|
36 (20.9%)
|
21 (28.8%)
|
|
TNM stage
|
|
I
|
87 (44.8%)
|
74 (43.0%)
|
23 (31.5%)
|
|
II
|
32 (16.5%)
|
34 (19.8%)
|
20 (27.4%)
|
|
III
|
75 (38.7%)
|
64 (37.2%)
|
30 (41.1%)
|
|
Histological type
|
|
ADC
|
95 (49.0%)
|
89 (51.7%)
|
47 (64.4%)
|
|
SCC
|
88 (45.3%)
|
76 (44.2%)
|
26 (35.6%)
|
|
ADC/SCC
|
11 (5.7%)
|
7 (4.1%)
|
0 (0.0%)
|
|
Tumor size (cm)
|
|
< 5
|
108 (55.7%)
|
97 (56.4%)
|
31 (42.5%)
|
|
≥ 5
|
86 (44.3%)
|
75 (43.6%)
|
42 (57.5%)
|
|
Differentiation
|
|
Well/moderate
|
126 (64.9%)
|
105 (61.0%)
|
43 (58.9%)
|
|
Poor
|
68 (35.1%)
|
67 (39.0%)
|
30 (41.1%)
|
|
Lymphatic metastasis
|
|
No
|
105 (54.1%)
|
81 (47.1%)
|
45 (61.6%)
|
|
Yes
|
89 (45.9%)
|
91 (52.9%)
|
28 (38.4%)
|
|
Follow-up time (month)
|
|
Median (IQR)
|
37 (24-62)
|
36 (23-54%)
|
22 (14-35)
|
|
Smoking history
|
|
No
|
79 (40.7%)
|
62 (36.0%)
|
33 (45.2%)
|
|
Yes
|
115 (59.3%)
|
110 (64.0%)
|
40 (44.8%)
|
|
Family cancer history
|
|
No
|
161 (83.0%)
|
151 (87.8%)
|
71 (97.3%)
|
|
Yes
|
33 (17.0%)
|
21 (12.2%)
|
2 (2.7%)
|
- SD standard deviation, ADC adenocarcinoma, SCC squamous cell carcinoma, IQR inter-quartile range
